Letermovir for the compassionate therapeutic use of cytomegalovirus infection

Eur J Clin Microbiol Infect Dis. 2020 Sep 11. doi: 10.1007/s10096-020-03990-w. Online ahead of print.

ABSTRACT

PURPOSE: Data on the efficacy, dosing and safety of letermovir for the compassionate therapeutic use of CMV infections are limited.

METHODS: Clinical and virological efficacy of letermovir was assessed in a retrospective single-centre study of patients who received letermovir for the compassionate therapeutic use of CMV infections.

RESULTS: Letermovir initiation yielded prompt treatment response in 7 out of 9 patients (77.7%).

CONCLUSION: Letermovir may be an effective and well tolerated option in the compassionate treatment of CMV infections, although recurrence of CMV and emergence of resistance may be issues.

PMID:32914220 | DOI:10.1007/s10096-020-03990-w